Dermatomyositis Clinical Trial
Official title:
Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
The Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), established in 2008, is a one-site database study conducted at the University of Pennsylvania. The database has yielded valuable information and clinical insights into the pathophysiology, disease processes, including psychological responses, treatments and quality of life associated with dermatomyositis. The CDASI database incorporates the Cutaneous Dermatomyositis Disease Area and Severity Index), a validated outcome measure of disease responsiveness in patients, and other assessment tools, surveys and patient information to help validate the clinical course and quality of life of patients with dermatomyositis. The CDASI database has led to publication of comparison studies of CDASI and other clinical instruments and the effect of dermatomyositis on Quality of Life (QoL). The CDASI database is an ongoing resource that enables clinicians to evaluate the evolving clinical changes, treatment modalities and patient response to a challenging disease. Data will be analysed over a 5 years.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
| Not yet recruiting |
NCT06284954 -
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
|
Phase 2 | |
| Completed |
NCT01906372 -
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
|
Phase 2 | |
| Completed |
NCT01813617 -
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
| Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
| Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
| Recruiting |
NCT05832034 -
Add-on Intravenous Immunoglobulins in Early Myositis
|
Phase 2 | |
| Recruiting |
NCT05979441 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
|
Phase 3 | |
| Not yet recruiting |
NCT05027152 -
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
|
N/A | |
| Active, not recruiting |
NCT04723303 -
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
|
Early Phase 1 | |
| Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05437263 -
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
|
Phase 3 | |
| Active, not recruiting |
NCT04044690 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
|
Phase 3 | |
| Recruiting |
NCT05523167 -
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06004817 -
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
|
||
| Recruiting |
NCT03324152 -
Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
| Completed |
NCT02043548 -
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
|
Phase 2 | |
| Completed |
NCT03414086 -
Predictor of Clinical Response to Acthar in Myositis
|
||
| Completed |
NCT04628936 -
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
|
Phase 2 | |
| Recruiting |
NCT03293615 -
Exercise Capacity of Patients With Dermatomyosis
|
N/A |